Aigen Investment Management, LP Mannkind Corp Transaction History

Aigen Investment Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$4.05 - $5.43 $131,746 - $176,637	32,530 New	32,530 $169,000
Q4 2023 Feb 09, 2024	BUY	$3.34 - $4.29 $76,415 - $98,150	22,879 Added 21.89%	127,386 $463,000
Q3 2023 Nov 13, 2023	BUY	$3.91 - $5.45 $319,579 - $445,450	81,734 Added 358.91%	104,507 $431,000
Q2 2023 Aug 14, 2023	SELL	$3.72 - $4.79 $178,712 - $230,116	-48,041 Reduced 67.84%	22,773 $92,000
Q1 2023 May 15, 2023	BUY	$3.95 - $5.63 $279,715 - $398,682	70,814 New	70,814 $290,000

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.75B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.